Thus, we studied the patient characteristics and survival outcomes of a retrospective cohort of patients from a single U.S. institution diagnosed with AM or MM who received treatment with FDA‐approved single‐agent anti‐PD‐1 (nivolumab or pembrolizumab) therapy as the standard of care for metastatic or unresectable disease. Here, PDCD1 is linked to acute myeloblastic leukemia with maturation.